Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2012

View Archived Issues

New diacylglycerol O-acyltransferase 1 inhibitors designed

New motilin receptor agonists divulged by Daiichi Sankyo

Research at Merck & Co. yields novel candidate hepatitis C therapies

Novartis designs novel IL-12RB1-targeted antibodies

Panacea Biotec develops new neurotransmitter transporter ligands

Scientists in Japan present new agents active against drug-resistant HIV-1

First dual SPK 1/2 inhibitors discovered at Amgen

Scientists in China develop vaccine to prevent atherosclerosis in persons with diabetes

Mecasermin shows promise in Rett's syndrome

Pharmanest begins phase I trial of product for relief of pain associated with IUD insertion

Tolero and MannKind enter agreement for BTK inhibitors

Liposomal GAP-107B8 has promising pharmacokinetics in rats

FDA accepts lomitapide NDA for review

Pivotal iferanserin trial advances

Ampio completes day 84 analysis of Ampion-In-Knee study

First drug launched to reduce toxic plasma methotrexate levels

FDA approves new therapy for type 1 Gaucher's disease

Vernalis completes phase I study of adenosine A2A receptor antagonist

Study assesses Ampligen administered with FluMist

Prana Biotechnology enrolls first patient in Reach2HD study

Recruitment complete in phase IIb Synavive trial

E.U. grant issued to support development of drug for fetal growth restriction

First-in-class PI3K-delta-specific agent advances to phase III testing

AnaptysBio and Gilead Sciences sign antibody discovery partnership

ISTA reports on phase II seasonal allergic rhinitis study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.